Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1543)	3/14/2000 9:17:00 AM
From: nigel bates	Read Replies (2) of 4974

March 14 /PRNewswire/ -- Transgenomic, Inc. announced today that it has filed a registration statement with the Securities and Exchange Commission for a public offering of its Common Stock, all of which will be sold by the Company. The terms of the offering are not yet disclosed and will be made only by prospectus Viragen, Inc. (OTC Bulletin Board: VRGN - news) today announced an agreement to increase to $60 million the equity financing through Ladenburg Thalmann & Co. Inc. (http://www.ladenburg.com), its investment banking firm. Viragen is an emerging biopharmaceutical company engaged in the research and development of immunomodulatory therapeutic products, including natural alpha interferon and human monoclonal antibodies, for the treatment of various diseases and immune disorders. Originally, Viragen and Ladenburg agreed to a proposed financing of $30 million for utilization over a two-year period. Viragen and Ladenburg now anticipate completion of the $60 million capital raising program prior to the end of 2000. nig

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next